Merus to Present at the 2025 Wells Fargo Healthcare Conference
Merus (NASDAQ:MRUS), an oncology company specializing in multispecific antibodies and antibody drug conjugates, announced its participation in the upcoming 2025 Wells Fargo Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Merus (NASDAQ:MRUS), an oncology company specializing in multispecific antibodies and antibody drug conjugates, announced its participation in the upcoming 2025 Wells Fargo Healthcare Conference. Bill Lundberg, M.D., President and CEO, will engage in a fireside chat on September 4, 2025, at 3:45 p.m. ET.
The presentation will be accessible via webcast on the company's Investors webpage, with a recording available for limited time afterward.
Details
News Market Reaction – MRUS
On Aug 28, the day this news came out, MRUS closed 1.75% below the previous close.
Data tracked by StockTitan Argus for the Aug 28 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 3:45 p.m. ET.
The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.
About Merus
Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, LinkedIn and Bluesky.
Multiclonics®, Biclonics®, Triclonics® and ADClonics® are registered trademarks of Merus N.V.
Investor and Media Inquiries:
Sherri Spear
Merus N.V.
SVP Investor Relations and Strategic Communications
617-821-3246
s.spear@merus.nl
Kathleen Farren
Merus N.V.
Director IR/Corp Comms
617-230-4165
k.farren@merus.nl
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.